Clinical Trials

Other hematologic neoplasm

87 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT01702064 2021-01-05

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

11 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01077544 2020-12-29

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

15 enrolled 20 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01223898 2020-12-09

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

19 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

11 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00384228 2020-12-08

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

42 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01279473 2020-12-08

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

42 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01914484 2020-11-02

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

4 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01274351 2020-09-01

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

112 enrolled 11 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01528085 2020-07-30

Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

79 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01744665 2020-03-10

ENESTgoal

59 enrolled 18 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

28 enrolled 10 charts

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02272777 2019-08-19

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

225 enrolled 7 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01294618 2019-05-28

NILOPEG

60 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02253277 2019-05-01

CoRNea

5 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01535391 2018-08-06

CML0811

109 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00809211 2018-07-24

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

40 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03332511 2017-11-06

ENESTKorea

Other hematologic neoplasm

110 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT00702403 2017-08-10

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

40 enrolled 12 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00264160 2017-03-06

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Phase 2/3 Completed

36 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01126892 2017-02-28

ENACT

6 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01061177 2017-02-24

'MACS1252

Other hematologic neoplasm

1,090 enrolled 24 charts

Leukemia, Philadelphia Chromosome

NCT00786812 2017-02-23

MACS0439

89 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01368523 2016-11-16

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

19 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00760877 2016-11-08

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

207 enrolled 9 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00750659 2016-04-20

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02733445 2016-04-11

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Completed

2,650 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01043874 2016-04-08

MACS0911

45 enrolled 9 charts